Oxford University breakthrough on global COVID-19 vaccine
Preliminary phase III data (n>24,000; 131 Covid-19 cases) suggest ChAdOx1 nCoV-2019 vaccine is 70.4% effective, with 90% efficacy if administered at half dose then full dose, or 62% efficacy if administered in 2 full doses. A reduction in asymptomatic infections also observed.
Source:
Oxford University
SPS commentary:
Additional findings include the following:
According to the BBC, Oxford's manufacturing partner, AstraZeneca, is preparing to make three billion doses worldwide.
The Oxford vaccine, at a price of around £3, also costs far less than Pfizer's (around £15) or Moderna's (£25) vaccines.